Completed PHASE2 INTERVENTIONAL 4-arm NCT06501534

A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Conditions Gout Hyperuricemia

Interventions Febuxostat IBI128

Updated 4 times since 2024 Last updated: Mar 26, 2025 Started: Jul 10, 2024 Primary completion: Dec 13, 2024 Completion: Jan 9, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gout and Hyperuricemia and is currently completed. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Oct 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE2

Status: Not Yet Recruiting → Active Not Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innovent Biologics (Suzhou) Co. Ltd.

Data source: Innovent Biologics (Suzhou) Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China